Literature DB >> 24529557

Comparison of media and serum supplementation for generation of monophosphoryl lipid A/interferon-γ-matured type I dendritic cells for immunotherapy.

Sonja T H M Kolanowski1, Lathees Sritharan1, Suzanne N Lissenberg-Thunnissen1, Gijs M W Van Schijndel1, S Marieke Van Ham1, Anja ten Brinke2.   

Abstract

BACKGROUND AIMS: Ex vivo-generated monocyte-derived dendritic cells (DCs) matured with monophosphoryl lipid A (MPLA) and interferon-γ (IFN-γ) can be used as cancer immunotherapy. MPLA/IFN-γ DCs induce Th1 T cell responses and have migratory capacity. Different culture regimens have been used for generation of immunotherapeutic DCs, with varying results. In the present study, culture conditions for MPLA/IFN-γ-matured type I DCs were optimized for clinical application.
METHODS: DCs were generated from monocytes in the clinical grade culture media CellGro DC, AIM V or X-VIVO 15 in the absence or presence of 2% human serum (HS) and matured with the use of MPLA/IFN-γ. DC yield and DC functionality were assessed. DC functionality was determined by means of analysis of cytokines in culture supernatant, migratory capacity, expression of co-stimulatory molecules, T cell stimulatory capacity of DCs and T helper cell (Th) polarization by the DCs.
RESULTS: DCs generated in the presence of 2% HS produced low amounts of pro-inflammatory cytokines and could not migrate irrespective of the medium used. In the absence of HS, MPLA/IFN-γ DCs generated in X-VIVO did not migrate either. MPLA/IFN-γ DCs generated in AIM V have slightly lower capacity to induce Th1 cells than do DCs generated in CellGro or X-VIVO.
CONCLUSIONS: Addition of HS to different GMP culture media is detrimental for pro-inflammatory DC maturation and migration. In the absence of serum, CellGro is the most optimal medium tested for generation of migratory and Th1-inducing MPLA/IFN-γ DCs for cancer immunotherapy.
Copyright © 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  clinical grade dendritic cells; culture media; immunotherapy; monophosphoryl lipid A; serum

Mesh:

Substances:

Year:  2014        PMID: 24529557     DOI: 10.1016/j.jcyt.2013.12.005

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  6 in total

Review 1.  Dendritic cell-based immunotherapy.

Authors:  Rachel L Sabado; Sreekumar Balan; Nina Bhardwaj
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

Review 2.  Plant-derived polysaccharides activate dendritic cell-based anti-cancer immunity.

Authors:  Siambi Kikete; Li Luo; Beitian Jia; Li Wang; Gregory Ondieki; Yuhong Bian
Journal:  Cytotechnology       Date:  2018-03-19       Impact factor: 2.058

Review 3.  Strategies for developing and optimizing cancer vaccines.

Authors:  Hoyoung M Maeng; Jay A Berzofsky
Journal:  F1000Res       Date:  2019-05-13

Review 4.  Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.

Authors:  Beatris Mastelic-Gavillet; Klara Balint; Caroline Boudousquie; Philippe O Gannon; Lana E Kandalaft
Journal:  Front Immunol       Date:  2019-04-11       Impact factor: 7.561

5.  Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses.

Authors:  Yunkai Yang; Xiaohan Guo; Bo Hu; Peng He; Xiaowu Jiang; Zuohuan Wang; Huaxing Zhu; Lina Hu; Minghua Yu; Meiqing Feng
Journal:  Acta Pharm Sin B       Date:  2020-08-25       Impact factor: 11.413

6.  Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.

Authors:  Marco Dionisi; Claudia De Archangelis; Federico Battisti; Hassan Rahimi Koshkaki; Francesca Belleudi; Ilaria Grazia Zizzari; Ilary Ruscito; Christian Albano; Alessandra Di Filippo; Maria Rosaria Torrisi; Pierluigi Benedetti Panici; Chiara Napoletano; Marianna Nuti; Aurelia Rughetti
Journal:  Front Immunol       Date:  2018-11-05       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.